On September 2, 2026, a UC Berkeley group published a paper in Nature reporting that semaglutide, started late in life, extended lifespan in mice. Median survival in the treated animals reached 834 days against 742 days in untreated controls — about 12%, or close to 100 extra days. The treatment did not begin in young animals: dosing started at 20 months, an age ageing researchers commonly describe as roughly analogous to a human in their early sixties.
That detail is what pushed the study into mainstream coverage this week. The finding is not "a weight-loss drug makes mice thinner." It is that GLP-1 receptor activation started in already-old animals reproduced most of the functional signature of calorie restriction — the most reliable lifespan intervention in laboratory biology — and in a few measures went past it. Below is what was actually reported, the human data that exists, the criticism the paper has already drawn, and where the read-through lands for anyone tracking the longevity peptide category.
Research-context information only. Compounds discussed below are research peptides and supplements; some are investigational drugs not approved by the FDA. Protocols, doses, and reactions reported come from published research and self-reported community sources. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What the Nature Paper Reported
The study (Feng et al., Nature 2026, PMID 42686906) came out of Danica Chen's lab in Berkeley's Department of Metabolic Biology and Nutrition, with co-authors at the National Institute on Aging and the University of Copenhagen. Funding came from the NIA and the National Institute of Food and Agriculture.
| What was tested | What was reported |
|---|---|
| Animals | Female C57BL/6 mice, treatment initiated at 20 months of age |
| Intervention | GLP-1 receptor agonist semaglutide; three months in the functional cohort, continued to end of life in the survival cohort |
| Median lifespan | 834 days treated vs 742 days control — roughly 12%, close to 100 days |
| Physiological function | Improved muscle function and cognitive function versus untreated controls |
| Ageing hallmarks | Attenuated hallmarks of ageing; reduced inflammatory signature and improved regenerative capacity markers |
| Molecular level | Modulation of nutrient sensors and conserved genetic regulators of ageing |
| Comparator arm | Matched 24% calorie restriction over a five-month longitudinal comparison |
The abstract's own framing is the most careful sentence in the paper: GLP-1 receptor activation initiated late in life "slows ageing and extends lifespan in female mice, supporting its function as a calorie restriction mimetic." Female mice. Not mammals. Not people.
One disclosure in the paper is worth reading alongside the result: the Regents of the University of California have filed a patent application covering GLP-1 receptor agonists for healthy ageing. That does not invalidate anything, but it is the kind of detail that belongs next to a longevity headline.
The Calorie Restriction Comparison — and the Question It Left Open
The more interesting half of the paper is the head-to-head against calorie restriction. Across a five-month longitudinal comparison against a matched 24% calorie-restricted group, semaglutide preserved baseline function and reproduced many of the functional benefits of restriction. On three measures the treated animals were reported to do better than the restricted ones: exploratory drive, spatial memory, and glucose control.
There was also a metabolic divergence. Calorie-restricted animals showed the expected drop in metabolic rate. The semaglutide-treated animals largely did not — which is the mechanistic hook the authors use to argue the drug is doing something beyond simply reducing calorie intake.
That framing has already drawn pushback. Nir Barzilai of Albert Einstein College of Medicine, quoted in Scientific American's coverage, put the missing arm plainly: "Maybe calorie restriction increases the lifespan more? The data is not there, and it bugs me." The lifespan arm compared semaglutide against untreated controls. The calorie-restriction comparison ran five months and measured function, not survival. So the headline number — 12% — has no restriction comparator behind it.
Chen was equally direct about the mechanism question in the same coverage: "The short answer is: we don't know yet."
The Human Evidence Is One Post Hoc Analysis
The gap between the rodent result and anything human is wide, and there is exactly one randomized dataset in it.
Corley and colleagues (Nature Communications 2026, PMID 42156721) ran an epigenetic age analysis on blood from a 32-week randomized, double-blind, placebo-controlled phase 2b trial of semaglutide in adults with HIV-associated lipohypertrophy (NCT04019197; semaglutide n=45, placebo n=39). In adjusted analyses they reported reductions across second- and third-generation clocks:
| Epigenetic measure | Reported semaglutide effect vs placebo |
|---|---|
| PhenoAge | −4.9 years/year (p = 0.004) |
| PCGrimAge | −3.1 (p = 0.007) |
| GrimAge V2 | −2.3 (p = 0.009) |
| OMICmAge | −2.2 (p = 0.009) |
| RetroAge | −2.2 (p = 0.030) |
| DunedinPACE | −0.09 units, 9% slower pace (p = 0.01) |
The authors' own limitations paragraph is the part that rarely survives into secondary coverage: the analysis was post hoc and not pre-specified, the sample was modest, the cohort was HIV-specific, and follow-up ran 32 weeks. Their conclusion was that prospective trials are needed to determine whether GLP-1 receptor agonists can be repurposed as gerotherapeutics — not that they have been. A separate smaller pilot in the SLIM LIVER study (npj Aging 2026, PMID 42014432) looked at the same question in a different cohort.
Two points follow. Epigenetic clocks are surrogate markers, not survival. And a 32-week readout in one clinical population is not a longevity trial in healthy adults, which is the study nobody has run.
What This Means for Peptide Buyers
Headline longevity data reliably moves demand in the research peptide channel, and the practical picture has not changed much: the compound in the study is the same semaglutide already stocked across the market, and no vendor sells an "anti-ageing formulation" of it that differs from what is already listed.
None of the compounds below is sold or marketed for anti-ageing or lifespan use. They are listed here as the same research-grade material the cited studies used, for readers comparing sourcing, and no GLP-1 receptor agonist is approved by any regulator for the treatment or prevention of ageing.
Vendor links below are affiliate partnerships — we may earn a commission at no added cost to you.
- Semaglutide is the molecule the Nature paper actually tested, and it is the most widely stocked GLP-1 compound in the research channel. COA-verified pricing and current coupon codes are compared in the semaglutide buying guide, with reconstitution detail in the semaglutide reconstitution guide and vendor rankings on /best/semaglutide.
- Tirzepatide and retatrutide are the incretin compounds most often cross-shopped against it. Neither has been tested in a lifespan study of any kind — the ageing data described above is semaglutide-specific and should not be read across the class. Vendor comparisons: tirzepatide, retatrutide.
- The longevity-category peptides — epitalon, NAD+ and MOTS-c — sit in a different evidence bracket entirely. None of them has a mammalian lifespan result of the quality reported here, which is worth knowing before treating the categories as interchangeable.
- The broader category view is in best peptides for anti-aging, which covers what each compound has and has not been shown to do.
Every active vendor discount across the metabolic and longevity categories is listed on the deals page.
